CON trades 2.8% below Wall Street's consensus target of $31.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CON achieves its forward estimates and maintains a stable P/E multiple of 19.9x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Concentra Group Holdings Parent, Inc. (CON) has a Wall Street consensus price target of $31.00, based on estimates from 6 covering analysts. With the stock currently trading at $30.15, this represents a potential upside of +2.8%. The company has a market capitalization of $3.86B.
Analyst price targets range from a low of $30.00 to a high of $32.00, representing a 6% spread in expectations. The median target of $31.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CON trades at a trailing P/E of 23.2x and forward P/E of 19.9x. Analysts expect EPS to grow +9.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $38.90, with bear and bull scenarios of $24.51 and $51.26 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AMSFAMERISAFE, Inc. | $634M | $33.75 | $44.50 | +31.9% | Buy | 16.1x | 6 |
OHIOmega Healthcare Investors, Inc. | $14.3B | $48.06 | $50.43 | +4.9% | Hold | 24.2x | 28 |
ACHCAcadia Healthcare Company, Inc. | $2.5B | $27.42 | $28.33 | +3.3% | Buy | 18.2x | 25 |
SEMSelect Medical Holdings Corporation | $2.1B | $16.54 | $17.75 | +7.3% | Hold | 13.6x | 14 |
USPHU.S. Physical Therapy, Inc. | $1.0B | $68.78 | $96.00 | +39.6% | Buy | 23.8x | 13 |
ATIATI Inc. | $27.0B | $197.40 | $175.00 | -11.3% | Buy | 44.7x | 29 |
ALHCAlignment Healthcare, Inc. | $4.7B | $23.19 | $24.33 | +4.9% | Buy | 121.7x | 16 |
CCRNCross Country Healthcare, Inc. | $427M | $13.22 | $12.50 | -5.4% | Hold | 142.9x | 14 |
AMNAMN Healthcare Services, Inc. | $1.3B | $32.76 | $27.00 | -17.6% | Buy | 12.3x | 17 |
OPCHOption Care Health, Inc. | $3.4B | $21.82 | $31.22 | +43.1% | Buy | 11.9x | 14 |
Quick answers to the most common questions about buying CON stock.
The consensus price target for CON is $31, close to the current price of $30.15 (2.8% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
CON has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $31 implies 2.8% upside from current levels.
With a forward P/E of 19.8682x, CON trades at a relatively low valuation. The consensus target of $31 implies 2.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $32 for CON, while the most conservative target is $30. The consensus of $31 represents the median expectation. Our quantitative valuation model projects a bull case target of $51 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CON is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CON stock forecast based on 6 Wall Street analysts shows a consensus price target of $31, with estimates ranging from $30 (bear case) to $32 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $39, with bear/bull scenarios of $25/$51.
Our quantitative valuation model calculates CON's fair value at $39 (base case), with a bear case of $25 and bull case of $51. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
CON trades at a forward P/E ratio of 19.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 23.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
CON appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $31 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CON analyst price targets range from $30 to $32, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31 consensus represents the middle ground. Our model's $25-$51 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.